Replies to post #10732 on CryoPort Inc (CYRX)

[mikeslife]

To me this is the most eye opening statement in your post:

"Despite the vast resources and capabilities of these competitors, all of the leading-edge, top names in the regenerative therapy market; Novartis, Kite, Bluebirdbio, Juno have chosen to partner with Cryoport. As of last year, they were supporting 23 of the 28 CAR-T clinical programs, and as of last quarter were supporting 172 of 899 clinical trials (18%) in regenerative therapy".

To be getting commitments from major companies is a huge accomplishment for a little "pip squeak" outfit like CYRX. If we are able to get only 3% of the market by 2021 we will be close to a 50 million dollar a year company. I feel 3% is easily achievable given our current and future alliances and market share could go much higher.

I was not aware of the aquisition of Marken late last year so I guess our relationsip with UPS is less than ideal from this point forward.

Here is a little info. I found on the internet regarding the latest acquisition

Feb. 1.17 | About: United Parcel (UPS) by Charles Fournier

Marken Acquisition (completed December 2016)

UPS completed its acquisition of Marken on December 22, 2016. The acquisition of Marken follows multiple UPS acquisitions that have expanded the company's healthcare logistics services portfolio.

Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. It maintains the leading position for Direct to Patient services and biological sample shipments and offers a state-of-the-art Good Manufacturing Practices (GMP) compliant depot network and logistic hubs.

GMP, by the way, is a system for ensuring that products are consistently produced, controlled, and delivered according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.

Marken has almost 700 staff members in 45 locations worldwide, including 10 depots that are compliant with GMP. It manages 50,000 drug and biological shipments every month at all temperature ranges to more than 150 countries. Additional services include biological kit production, ancillary material sourcing, storage and distribution, and shipment lane qualifications.

Pharmaceutical companies, clinical research organizations, and contract manufacturers rely on Marken for collection and transportation of clinical trial material and investigational medicinal products. In addition, they rely on Marken for the shipment of biological samples from these sites to central laboratories. These shipments are time- and temperature-sensitive, and their rapid, on-spec delivery is a key factor in the treatment of patients and the success of the clinical trial.